Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 March 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd has touched a new 52-week low of Rs.28.01 today, marking a significant decline amid continued underperformance relative to its sector and benchmark indices. The stock has now recorded losses for three consecutive days, accumulating a negative return of 8.59% over this period.

Biofil Chemicals & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, quality indicators, and technical outlook. The downgrade reflects a combination of flat recent financial trends, deteriorating profitability measures, and a valuation profile that, while attractive, is overshadowed by weak fundamentals and underwhelming market returns.

Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This recalibration in price-to-earnings (P/E) and price-to-book value (P/BV) ratios offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

Shares of Biofil Chemicals & Pharmaceuticals Ltd surged to hit the upper circuit limit on 9 Feb 2026, propelled by robust buying interest and a near 10% intraday gain. The stock’s performance outpaced its sector and benchmark indices, reflecting renewed investor confidence despite a recent downtrend.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Shares of Biofil Chemicals & Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, plunged sharply to hit the lower circuit limit on 5 Feb 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹37.54, down 10.0% on the day, marking its maximum permissible daily loss and underperforming both its sector and the broader market indices.

Shares of Biofil Chemicals & Pharmaceuticals Ltd plunged sharply on 4 Feb 2026, hitting the lower circuit limit of 8.26% amid intense selling pressure. The stock underperformed its sector and broader market indices, reflecting mounting investor concerns and a sudden reversal after a brief rally.

Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness despite a complex performance backdrop. This article analyses the recent valuation changes, compares them with industry peers, and examines the implications for investors amid the company’s mixed return profile.

Shares of Biofil Chemicals & Pharmaceuticals Ltd surged to hit the upper circuit limit on 3 February 2026, propelled by intense buying interest and a significant price rally. The stock closed with a maximum daily gain of 9.99%, reflecting strong investor confidence despite its current sell rating, underscoring a notable market event in the Pharmaceuticals & Biotechnology sector.

Biofil Chemicals & Pharmaceuticals Ltd witnessed a remarkable surge on 2 Feb 2026, hitting its upper circuit limit with a 19.99% gain to close at ₹42.13. The stock demonstrated strong buying momentum, outpacing its sector and broader market indices, driven by heightened investor interest and significant unfilled demand.

Biofil Chemicals & Pharmaceuticals Ltd witnessed a remarkable surge on 1 Feb 2026, hitting its upper circuit limit of 20% to close at ₹35.11. This sharp rally was driven by intense buying interest, resulting in the stock outperforming its sector and broader market indices amid a backdrop of subdued investor participation and regulatory trading restrictions.

Biofil Chemicals & Pharmaceuticals Ltd has touched a new 52-week low of Rs.28.79, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Biofil Chemicals & Pharmaceuticals Ltd has reached a new 52-week low of Rs.28.9, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.